<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20072">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01987011</url>
  </required_header>
  <id_info>
    <org_study_id>MG1109_P3</org_study_id>
    <nct_id>NCT01987011</nct_id>
  </id_info>
  <brief_title>Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers</brief_title>
  <official_title>Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Immunogenicity and Safety of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <authority>South Korea: Ministry of Food and Drug Safety(MFDS)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and safety of the
      investigational vaccine in the subjects during their participation in the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Percentage of subjects achieving post-vaccination Hemagglutination Inhibition(HI) antibody titer â‰¥ 1:40</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects achieving post-vaccination seroconversion for Hemagglutination Inhibition(HI) antibody</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>GMR(Geometric Mean Ratio) of Hemagglutination Inhibition(HI) antibody titer at post-vaccination compared to pre-vaccination</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects reporting solicited adverse events from the date of vaccination until 7 days after each vaccination</measure>
    <time_frame>Each vaccination ~ 7 days after each vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects reporting unsolicited adverse events from the date of 1st vaccination until 24weeks after 2nd vaccination</measure>
    <time_frame>1st vaccination ~ 24 weeks after 2nd vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT(Geometric Mean Titer) of Hemagglutination Inhibition(HI) antibody titer pre-vaccination and post-vaccination</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT(Geometric Mean Titer) and GMR(Geometric Mean Ratio) of neutralizing antibody titer pre-vaccination and post-vaccination</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs(body temperature, pulse)</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The results of physical examinations</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab results(Hematology, Blood chemistry, Urinalysis)</measure>
    <time_frame>1st vaccination ~ 21 days after 2nd vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>MG1109</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG1109</intervention_name>
    <description>Investigational Product : MG1109 Dose : 0.5 mL Intramuscularly injection, twice at an interval of 21 days</description>
    <arm_group_label>MG1109</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults who are available for follow-up during the study

        Exclusion Criteria:

          -  Subjects with history of exposure to the H5N1 subtype or H5N1 subtype vaccine

          -  Subjects with immune system disorder including immune deficiency disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woo Joo Kim, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Inchon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University Of Korea ST. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>July 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Avian influenza</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
